NVONOVO NORDISK A S

NYSE novonordisk.com


$ 134.96 $ -0.85 (-0.63 %)    

Wednesday, 21-Aug-2024 15:59:58 EDT
QQQ $ 482.88 $ 2.24 (0.47 %)
DIA $ 408.91 $ 0.43 (0.11 %)
SPY $ 560.81 $ 1.92 (0.34 %)
TLT $ 98.72 $ 0.06 (0.06 %)
GLD $ 232.16 $ -0.31 (-0.13 %)
$ 134.96
$ 134.91 x 100
-- x --
-- - --
$ 86.02 - $ 147.60
2,410,507
na
608,670
$ 0.66
$ 0.00
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wegovy-now-available-through-sesames-249-monthly-compounded-program-despite-supply-shortages

Sesame introduces an affordable weight loss program with compounded versions of Wegovy amid supply shortages. The program provi...

 novo-nordisk-vs-eli-lilly-beyond-the-weight-loss-drug-battle

Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatmen...

 ozempic-and-wegovy-linked-to-increased-suicidal-thoughts-in-observational-study-but-results-are-contested

A recent study in JAMA Network Open raises concerns about a potential link between GLP-1 drugs Ozempic and Wegovy and an increa...

 nsa-code-breaker-jim-simons-hedge-fund-renaissance-technologies--ozempic-wegovy-maker-novo-nordisk-along-with-nvidia-palantir-among-top-holdings

Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently di...

 cantor-fitzgerald-reiterates-overweight-on-novo-nordisk-maintains-160-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Novo Nordisk (NYSE:NVO) with a Overweight and maintains $160 price target.

 telehealth-firm-hims--hers-health-rides-high-on-demand-for-copycat-weight-loss-drugs-amid-supply-shortages

Hims & Hers Health has seen its stock rise over 120% due to soaring demand for its affordable compounded GLP-1 weight-loss ...

 doctors-struggle-to-secure-medicare-coverage-for-heart-patients-on-novo-nordisks-wegovy

Medicare patients struggle to access Novo Nordisk's Wegovy for heart disease treatment despite new guidelines, with many pl...

 roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market

Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron...

 dont-promote-copycat-weight-loss-drugs-amid-improved-supply-eli-lilly-asks-doctors-fda-evaluates

Eli Lilly issues cease-and-desist letters to healthcare providers, demanding they stop promoting compounded weight-loss drugs a...

 eli-lilly-smashed-estimates-thanks-to-unbelievable-demand-for-its-diabetes-and-weight-loss-blockbusters

On Thursday, Eli Lilly and Company (NYSE: LLY) reported its second quarter results, smashing estimates fueled by the popularity...

 weight-loss-drugs-like-ozempic-zepbound-may-reduce-cancer-risks-studies-suggest

GLP-1 agonists like Ozempic and Wegovy, known for treating obesity and diabetes, are now showing potential in reducing cancer r...

 eli-lillys-q2-sales-surge-36-analysts-cautious-on-future-supply-market-dynamics-optimistic-about-next-gen-oral-weight-loss-drug

Eli Lilly's Q2 revenue soared to $11.3 billion, surpassing forecasts. Mounjaro sales tripled and Zepbound revenue grew sign...

 bmo-capital-maintains-outperform-on-novo-nordisk-lowers-price-target-to-160

BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Outperform and lowers the price target fro...

Core News & Articles

Conference Call

 novo-nordisk-withdraws-wegovy-fda-heart-failure-submission-terminates-development-of-two-early-stage-assets

Novo Nordisk missed Q2 earnings estimates and announced plans to resubmit Wegovy STEP HFpEF trial results for FDA review in ear...

 wall-street-poised-for-second-day-of-gains-while-bank-of-japan-makes-reassurances-dollar-strengthens-against-yen-crude-prices-surge-whats-driving-markets-wednesday

The U.S.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION